Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goal-directed Treatment of Chronic Bowel Dysfunction
NCT04507945Phase 2Unknown
- Sponsor
- Nanjing University School of Medicine
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label trial of somatropin and glutamine in functional bowel disorder (FBD) and short bowel syndrome (SBS) (2 arms), sponsored by Nanjing University School of Medicine. Primary endpoint: nutrition index at 3 years. Status: unknown.
02
Drugs
somatropinglutamine
03
Conditions
functional bowel disorder (FBD)short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04507945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507945.